Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Ezetimibe for hypercholesterolemia.

Spencer Morris¹, Rob Tiller

¹Montgomery Center for Family Medicine, Greenwood Family Practice Residency, Greenwood, South Carolina, USA.

American Family Physician

|November 5, 2003

Summary

This summary is machine-generated.

Ezetimibe (Zetia) is a cholesterol absorption inhibitor that effectively lowers high cholesterol levels. It works in the small intestine without affecting fat-soluble vitamin absorption, offering a new treatment option.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Neuroanatomical correlates of neuropsychological dysfunction in pediatric pharmacoresistant epilepsy due to focal cortical dysplasia type II.

Epilepsia open·2026

Same author

Clinical use and radiological yield of magnetic resonance fingerprinting in epilepsy.

Epilepsia·2026

Same author

Utility of MR fingerprinting in differentiating epileptogenic from non-epileptogenic cortical malformations.

Journal of the neurological sciences·2025

Same author

Automated Whole-Brain Focal Cortical Dysplasia Detection Using MR Fingerprinting With Deep Learning.

Neurology·2025

Same author

Combining magnetic resonance fingerprinting with voxel-based morphometric analysis to reduce false positives for focal cortical dysplasia detection.

Epilepsia·2024

Same author

Possible post-COVID epilepsy: A review of epilepsy monitoring unit admissions during the two years of COVID-19 pandemic.

Epilepsy & behavior reports·2023

Same journal

For Post-stent Patients With Atherosclerotic Coronary Vascular Disease Who Are Taking an Anticoagulant, Adding Aspirin Worsens Outcomes.

American family physician·2026

Same journal

Nausea and Vomiting During Pregnancy.

American family physician·2026

Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

American family physician·2026

Same journal

Aerobic Exercise Is the Better Exercise Modality for Knee Osteoarthritis.

American family physician·2026

Same journal

Overscreening Leads to Overdiagnosis of MASLD.

American family physician·2026

Same journal

Type 2 Diabetes: Outpatient Insulin Management.

American family physician·2026

See all related articles

Area of Science:

Pharmacology
Gastroenterology
Metabolic Diseases

Background:

Primary hypercholesterolemia is a common condition requiring effective lipid-lowering therapies.
Cholesterol absorption plays a key role in maintaining cholesterol homeostasis.
Novel therapeutic targets for hypercholesterolemia are continuously being investigated.

Purpose of the Study:

To introduce Ezetimibe (Zetia) as a novel selective cholesterol absorption inhibitor.
To elucidate the mechanism of action of Ezetimibe in the small intestine.
To outline the therapeutic indications for Ezetimibe in managing hypercholesterolemia and related disorders.

Main Methods:

Ezetimibe selectively inhibits cholesterol absorption at the brush-border of the small intestine.
Studies confirm Ezetimibe does not significantly impact the absorption of bile acids, fatty acids, fat-soluble vitamins, or triglycerides.
Clinical trials evaluated Ezetimibe's efficacy in various hypercholesterolemia patient populations.

Main Results:

Ezetimibe effectively reduces dietary and biliary cholesterol absorption.
Monotherapy and combination therapy with statins demonstrate efficacy in lowering LDL cholesterol.
Ezetimibe is indicated for primary hypercholesterolemia, homozygous familial hypercholesterolemia, and homozygous sitosterolemia.

Conclusions:

Ezetimibe represents a new class of drugs targeting cholesterol absorption.
Its selective mechanism offers a distinct approach to managing hypercholesterolemia.
Ezetimibe provides a valuable therapeutic option, alone or with statins, for specific cholesterol-related conditions.